Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
IONS Ionis Pharmaceuticals, Inc. daily Stock Chart
IONS [NASD]
Ionis Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E111.90 EPS (ttm)0.51 Insider Own0.10% Shs Outstand136.48M Perf Week-0.05%
Market Cap7.80B Forward P/E145.87 EPS next Y0.39 Insider Trans-38.19% Shs Float124.96M Perf Month8.03%
Income63.70M PEG2.80 EPS next Q0.03 Inst Own89.50% Short Float9.83% Perf Quarter26.70%
Sales579.90M P/S13.46 EPS this Y214.20% Inst Trans0.02% Short Ratio12.37 Perf Half Y29.63%
Book/sh4.96 P/B11.53 EPS next Y214.70% ROA-2.40% Target Price58.54 Perf Year7.44%
Cash/sh14.35 P/C3.98 EPS next 5Y40.00% ROE-8.80% 52W Range39.07 - 59.81 Perf YTD5.77%
Dividend- P/FCF16.01 EPS past 5Y26.60% ROI14.60% 52W High-4.40% Beta2.40
Dividend %- Quick Ratio8.00 Sales past 5Y37.80% Gross Margin38.70% 52W Low46.35% ATR2.26
Employees547 Current Ratio8.00 Sales Q/Q22.90% Oper. Margin-12.70% RSI (14)59.47 Volatility3.20% 4.26%
OptionableYes Debt/Eq0.90 EPS Q/Q-51.50% Profit Margin-7.50% Rel Volume0.58 Prev Close58.26
ShortableYes LT Debt/Eq0.88 EarningsFeb 05 BMO Payout- Avg Volume993.29K Price57.18
Recom2.70 SMA206.40% SMA506.11% SMA20019.48% Volume581,041 Change-1.85%
Aug-08-18Reiterated Stifel Hold $48 → $47
Aug-07-18Reiterated Stifel Hold $55 → $48
May-08-18Downgrade Evercore ISI Outperform → In-line
Oct-06-17Resumed Goldman Sell $30
Aug-17-17Initiated Evercore ISI Outperform $65
Aug-09-17Reiterated Stifel Hold $42 → $50
Mar-10-17Downgrade Goldman Neutral → Sell
Dec-28-16Reiterated BMO Capital Markets Outperform $61 → $68
Dec-27-16Reiterated Leerink Partners Mkt Perform $40 → $47
Dec-27-16Reiterated Laidlaw Buy $59 → $65
Nov-10-16Resumed Leerink Partners Mkt Perform
Aug-10-16Reiterated Piper Jaffray Overweight $36 → $46
Aug-03-16Initiated Morgan Stanley Equal-Weight $37
Aug-02-16Reiterated Needham Buy $55 → $64
Aug-02-16Reiterated Barclays Equal Weight $26 → $41
May-27-16Reiterated Needham Buy $88 → $55
Jan-16-19 06:57AM  4 Defensive Stocks to Buy Amid Shutdown and Brexit Zacks
Jan-15-19 08:00AM  Pfizer Gets FDA's Priority Review for Rare Disease Candidate Zacks
Jan-14-19 04:23PM  This Biotech Stock Plunged On Its Looming Rivalry With Pfizer Investor's Business Daily
Jan-12-19 06:00PM  3 Top Biotech Stocks to Buy in January Motley Fool
Jan-02-19 03:48PM  Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018 Investor's Business Daily
07:05AM  Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference PR Newswire
06:00AM  Top Picks 2019- Ionis Pharmaceuticals IONS MoneyShow
Dec-31-18 07:51AM  4 of the Fastest Growing Biotech Stocks in 2019 Motley Fool +5.26%
Dec-21-18 04:26PM  Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug Investor's Business Daily
Dec-20-18 06:39PM  Ionis Pharmaceuticals outlines CEO succession plan MarketWatch
05:41PM  Ionis Announces Plans for Management Transitions in 2020 PR Newswire
07:20AM  New Research: Key Drivers of Growth for Baxter International, Sempra Energy, Nielsen Holdings Plc, ARRIS International plc, Ionis Pharmaceuticals, and KB Home Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Dec-14-18 12:47AM  Should You Buy Ionis Pharmaceuticals, Inc. (IONS)? Insider Monkey
Dec-13-18 09:26AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis Zacks
Dec-12-18 10:03AM  Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate Zacks
Dec-11-18 11:19AM  Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Expensive For A Reason? A Look At The Intrinsic Value Simply Wall St.
Dec-06-18 07:30AM  Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data GlobeNewswire
Nov-29-18 05:30PM  Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis Investor's Business Daily
07:30AM  International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product GlobeNewswire
Nov-27-18 07:00AM  First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting PR Newswire
Nov-19-18 05:00AM  Edited Transcript of IONS earnings conference call or presentation 6-Nov-18 4:30pm GMT Thomson Reuters StreetEvents
Nov-14-18 09:15AM  Stocks Not in a Bouncy Mood Yet Zacks
Nov-13-18 07:07AM  Ionis Pharmaceuticals to Present at Jefferies 2018 London Healthcare Conference PR Newswire
Nov-12-18 03:16PM  5 Pharma Stocks to Stay Away From InvestorPlace
12:50PM  Ionis Pharmaceuticals Collects Royalties -- and Spends It All Motley Fool
06:55AM  Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions GlobeNewswire
Nov-09-18 07:07AM  Ionis Pharmaceuticals to Host Investor Day PR Newswire
Nov-08-18 09:00AM  Recent Analysis Shows Automatic Data Processing, GTx, Ionis Pharmaceuticals, TriNet Group, Ternium S.A, and UNIVERSAL INSURANCE HOLDINGS INC Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
07:00AM  Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions GlobeNewswire
Nov-07-18 07:00AM  Ionis Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
Nov-06-18 05:48PM  Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript Motley Fool
08:30AM  Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:27AM  Ionis Pharmaceuticals: 3Q Earnings Snapshot Associated Press
07:00AM  Ionis Reports Third Quarter 2018 Financial Results PR Newswire
Oct-31-18 07:00AM  Advances in Ionis' Novel Antisense Technology to be Presented at 2018 Society for Neuroscience Meeting PR Newswire
Oct-24-18 08:00AM  Today's Research Reports on Trending Tickers: Sage Therapeutics and Ionis Pharmaceuticals ACCESSWIRE -5.79%
07:00AM  Ionis Pharmaceuticals to Hold Third Quarter 2018 Financial Results Webcast PR Newswire
Oct-23-18 07:00AM  Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize for Innovation in Science PR Newswire
Oct-22-18 08:45AM  Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology PR Newswire
Oct-17-18 10:00AM  Billionaire Tech Titans Award Millions to Make Scientists Stars Bloomberg
08:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Gogo, Jagged Peak Energy, Everbridge, Roku, Corium International, and Ionis Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Oct-11-18 07:00AM  Here's Why Ionis Pharmaceuticals Rose 12.9% in September Motley Fool
Oct-10-18 10:12AM  [$$] Ionis, Roche Reach New Collaboration Agreement The Wall Street Journal
09:27AM  Ionis's stock surges after Roche collaboration, which could be worth up to $759 million MarketWatch
09:07AM  Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases PR Newswire
Oct-08-18 07:00AM  Akcea Announces Changes to Board of Directors GlobeNewswire -7.65%
Oct-05-18 07:11PM  Cambridge's Akcea rebounds with FDA approval of first drug American City Business Journals
06:17PM  Akcea Therapeutics genetic disease treatment gets FDA approval Reuters
05:33PM  Akcea Announces Its Access and Distribution Strategy for TEGSEDI (inotersen) GlobeNewswire
05:32PM  Akcea and Ionis Receive FDA Approval of TEGSEDI (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults GlobeNewswire
Sep-27-18 09:32AM  When Will Ionis Pharmaceuticals Inc (NASDAQ:IONS) Become Profitable? Simply Wall St.
Sep-24-18 04:06PM  Ionis Announces the Appointment of Two New Board Members PR Newswire
Aug-29-18 09:23AM  Can Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Recover? Motley Fool
07:35AM  3 Big Stock Charts for Wednesday: PG&E, PepsiCo and Hewlett Packard Enterprise InvestorPlace
07:09AM  Ionis stock drops 13% as FDA fails to approve key drug MarketWatch
07:00AM  Ionis Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
Aug-28-18 04:34PM  Why Canopy Growth, Mitek Systems, and Ionis Pharmaceuticals Slumped Today Motley Fool -15.88%
12:51PM  Here's Why Ionis Pharmaceuticals and Akcea Therapeutics Plummeted Today Motley Fool
10:24AM  Akcea Plunges as Analysts Fear Wider Fallout From Drug Setback Bloomberg
08:45AM  Ionis Pharmaceuticals (IONS) Looks Good: Stock Adds 7.8% in Session Zacks
08:13AM  The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic Benzinga
Aug-27-18 05:47PM  After-hours buzz: AMD, AKCA, IONS & more CNBC +7.83%
05:30PM  FDA rejects rare disease drug developed by Cambridge's Akcea American City Business Journals
05:07PM  Akcea, Ionis shares drop after disappointing FDA decision MarketWatch
05:01PM  What Happened in the Stock Market Today Motley Fool
04:39PM  U.S. FDA declines to approve Akcea/Ionis genetic disease drug Reuters
04:30PM  Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA GlobeNewswire
02:59PM  Pfizer Slips Despite Mostly Positive Tafamidis Data; 4 Pharma Stocks Make Sympathy Moves Benzinga
01:07PM  Here's Why Alnylam Pharmaceuticals and Ionis Pharmaceuticals Jumped Today Motley Fool
08:38AM  Pfizer rare-disease drug results lift its shares and those of rival MarketWatch
Aug-23-18 10:02AM  Recent Analysis Shows Fitbit, Southwestern Energy, DAQO New Energy, ANGI Homeservices, Inc., Ionis Pharmaceuticals, and Cronos Group Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-22-18 03:52PM  Should Alnylam's and Ionis' Investors Be Worried About This Recent IPO? Motley Fool
Aug-20-18 11:59PM  Edited Transcript of IONS earnings conference call or presentation 7-Aug-18 3:30pm GMT Thomson Reuters StreetEvents
08:00AM  3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro Motley Fool
Aug-17-18 10:02PM  Heres Why Alnylams Shares Are Tumbling Motley Fool
Aug-16-18 06:06PM  UBS Commercial Mortgage Trust 2017-C3 -- Moody's affirms seven classes of UBS 2017-C3 Moody's
Aug-15-18 01:41PM  Akcea Therapeutics Soars as It Readies Its First Drug Launch Motley Fool
Aug-13-18 01:36PM  Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses Motley Fool
08:17AM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
Aug-11-18 02:30PM  Why Biogen's Stock Ripped Higher in July Motley Fool
Aug-09-18 01:29PM  Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript Motley Fool +5.79%
Aug-07-18 11:25AM  Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates Zacks
10:20AM  Ionis Pharmaceuticals: 2Q Earnings Snapshot Associated Press
09:37AM  Ionis (IONS) Posts Wider than Expected Loss in Q2, Sales Miss Zacks
09:30AM  Ionis Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
07:00AM  Ionis Reports Second Quarter 2018 Financial Results PR Newswire
Aug-06-18 04:05PM  Akcea Reports Financial Results and Highlights for Second Quarter 2018 GlobeNewswire
01:09PM  Alnylam Pharmaceuticals Is "Launch Ready" Motley Fool
Aug-03-18 02:46PM  Avoid Treating Biogen Like a Speculative Drug Stock InvestorPlace
Aug-02-18 04:05PM  IONIS-HTT Rx (RG6042) Granted PRIME Designation by the European Medicines Agency for the Treatment of People with Huntington's Disease PR Newswire
08:00AM  Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America PR Newswire
Aug-01-18 12:18PM  Is a Beat in Store for Ionis (IONS) This Earnings Season? Zacks
Jul-25-18 03:21PM  Biogen Posts Solid Earnings as the Biotech Waits for Clinical Trial Data Motley Fool
11:12AM  Why Every Investor Should Hold Shares of Biogen Stock InvestorPlace
Jul-24-18 07:00AM  Ionis Pharmaceuticals to Hold Second Quarter 2018 Financial Results Webcast PR Newswire
Jul-23-18 04:30PM  Akcea Therapeutics to Hold Second Quarter 2018 Financial Results Webcast GlobeNewswire
Jul-18-18 08:08AM  Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates Zacks
Jul-12-18 09:21AM  Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer Zacks
08:46AM  Is Ionis Pharmaceuticals, Inc. a Buy? Motley Fool
Jul-11-18 08:41AM  Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8% Zacks
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; Roche to develop therapeutics for the treatment of complement-mediated diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs, as well as a research collaboration agreement with Cerveau Technologies, Inc. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'NEIL PATRICK R.SVP Legal & General CounselJan 03Option Exercise37.234,400163,80818,584Jan 03 07:50 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 03Sale54.804,400241,12014,584Jan 03 07:50 PM
Monia Brett PChief Operating OfficerJan 02Sale53.5021411,44915,837Jan 03 07:42 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 19Option Exercise7.252,06314,95716,837Dec 20 05:55 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 19Sale52.052,063107,37914,774Dec 20 05:55 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 18Option Exercise7.252,00014,50016,774Dec 20 05:55 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 18Sale52.002,000104,00014,774Dec 20 05:55 PM
Monia Brett PChief Operating OfficerNov 23Option Exercise14.6934,000499,46049,841Nov 26 08:01 PM
Monia Brett PChief Operating OfficerNov 23Sale55.0034,0001,870,05815,841Nov 26 08:01 PM
BENNETT C FRANKSVP, Antisense ResearchNov 01Option Exercise14.6912,500183,62531,896Nov 01 07:34 PM
BENNETT C FRANKSVP, Antisense ResearchNov 01Sale49.5412,500619,24519,396Nov 01 07:34 PM
Monia Brett PChief Operating OfficerAug 27Option Exercise7.2316,493119,27424,834Aug 29 04:49 PM
Monia Brett PChief Operating OfficerAug 27Sale54.0016,493890,62215,841Aug 29 04:49 PM
BENNETT C FRANKSVP, Antisense ResearchAug 08Option Exercise14.6812,500183,52831,883Aug 09 06:34 PM
BENNETT C FRANKSVP, Antisense ResearchAug 08Sale45.0012,500562,50019,396Aug 09 06:34 PM
Monia Brett PChief Operating OfficerJul 24Sale47.031567,33715,841Jul 25 07:19 PM
WENDER JOSEPH HDirectorJul 17Option Exercise9.2630,000277,80068,916Jul 19 06:45 PM
LOSCALZO JOSEPHDirectorJul 03Option Exercise0.00667010,419Jul 03 03:20 PM
Castleman BreauxDirectorJul 03Option Exercise0.00667012,294Jul 03 03:13 PM
WENDER JOSEPH HDirectorJul 03Option Exercise0.00667038,916Jul 03 03:10 PM
BERTHELSEN SPENCER RDirectorJul 03Option Exercise0.00667094,094Jul 03 03:08 PM
KLEIN JOSEPH IIIDirectorJul 03Option Exercise0.00667012,606Jul 03 03:07 PM
LOSCALZO JOSEPHDirectorJul 01Option Exercise0.002,00009,752Jul 03 03:20 PM
Castleman BreauxDirectorJul 01Option Exercise0.002,000011,627Jul 03 03:13 PM
WENDER JOSEPH HDirectorJul 01Option Exercise0.002,000038,249Jul 03 03:10 PM
BERTHELSEN SPENCER RDirectorJul 01Option Exercise0.002,000093,427Jul 03 03:08 PM
KLEIN JOSEPH IIIDirectorJul 01Option Exercise0.002,000011,939Jul 03 03:07 PM
BERTHELSEN SPENCER RDirectorJun 25Option Exercise13.8815,000208,200100,727Jun 25 08:28 PM
BERTHELSEN SPENCER RDirectorJun 25Sale42.3015,000634,54291,427Jun 25 08:28 PM
MUTO FREDERICK TDirectorMay 31Option Exercise13.8815,000208,20022,127May 31 08:02 PM
MUTO FREDERICK TDirectorMay 31Sale46.4515,000696,7507,127May 31 08:02 PM
WENDER JOSEPH HDirectorMay 11Option Exercise13.8815,000208,20044,839May 11 09:00 PM
BENNETT C FRANKSVP, Antisense ResearchMay 11Option Exercise7.2512,50090,62531,614May 11 09:06 PM
BENNETT C FRANKSVP, Antisense ResearchMay 11Sale45.0012,500562,50019,114May 11 09:06 PM
WENDER JOSEPH HDirectorMay 11Sale45.3115,000679,61436,249May 11 09:00 PM
CROOKE STANLEY TChairman and CEOApr 17Option Exercise10.824,00043,2806,128Apr 19 05:22 PM
CROOKE STANLEY TChairman and CEOApr 17Option Exercise14.699,962146,34256,714Apr 19 05:22 PM
CROOKE STANLEY TChairman and CEOApr 17Sale44.404,000177,6004,128Apr 19 05:22 PM
CROOKE STANLEY TChairman and CEOApr 17Sale44.409,962442,31351,733Apr 19 05:22 PM
KLEIN JOSEPH IIIDirectorMar 29Option Exercise24.422,00048,84011,939Mar 30 03:51 PM
KLEIN JOSEPH IIIDirectorMar 29Sale46.152,00092,3009,939Mar 30 03:51 PM
KLEIN JOSEPH IIIDirectorMar 15Option Exercise24.422,00048,84010,839Mar 16 04:19 PM
KLEIN JOSEPH IIIDirectorMar 15Sale51.132,000102,2589,939Mar 16 04:19 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 12Option Exercise10.821,00010,82015,452Mar 13 09:14 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 12Sale55.001,00055,00014,452Mar 13 09:14 PM
KLEIN JOSEPH IIIDirectorFeb 28Option Exercise35.533,000106,59012,039Mar 01 05:52 PM
KLEIN JOSEPH IIIDirectorFeb 28Sale51.913,000155,7279,939Mar 01 05:52 PM
KLEIN JOSEPH IIIDirectorFeb 15Option Exercise35.533,000106,59011,539Feb 16 06:00 PM
KLEIN JOSEPH IIIDirectorFeb 15Sale48.993,000146,9849,939Feb 16 06:00 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 29Option Exercise10.823553,84114,752Jan 31 04:16 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 29Sale55.0035519,52514,452Jan 31 04:16 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 25Option Exercise10.826456,97915,097Jan 29 04:08 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 25Sale55.0064535,47514,452Jan 29 04:08 PM
open in yahoo | open in reuters | open in google